Alzheimer’s disease is a disease of memory associated with aging, affecting an estimated 5 million persons in the U.S. (a number that is estimated to triple by 2050). Current FDA-approved treatments have little effect on the overall course of the disease and there are several drugs in research trials that target a chemical called amyloid in the brain, seeking to lower levels of brain amyloid in the hope of slowing down disease progression. However, several of these drugs have failed in recent trials and new strategies – targeting different forms of amyloid or targeting the “downstream” effects of amyloid in the brain – are being pursued. Additionally, patients with Alzheimer’s disease suffer not only from cognitive symptoms but psychological symptoms including apathy, depression, and agitation. These symptoms add considerably to the burden suffered by patients and families and are current more responsive to treatments than the cognitive symptoms. We have recently reported that methylphenidate (brand name Ritalin) is beneficial for apathy, for example, and there are trials underway for treatments of agitation as well.
Paul B. Rosenberg, M.D., is Assistant Professor of Psychiatry and Behavioral Sciences in the Division of Geriatric Psychiatry and Neuropsychiatry of the Johns Hopkins School of Medicine and Johns Hopkins Bayview Medical Center. Dr. Rosenberg is Associate Director of the Memory and Alzheimer’s Treatment Center and the Lakeside Medical Unit at Johns Hopkins Bayview Medical Center.
Dr. Rosenberg’s research focuses on developing new treatments for Alzheimer’s Disease and studying biomarkers and risk factors that impact on treatment development. His current projects are focused on PET imaging and peripheral blood markers of neuroinflammation and amyloid deposition in Alzheimer’s Disease, depression as a risk factor for developing mild cognitive impairment and Alzheimer's Disease, and treatment of neuropsychiatric symptoms of Alzheimer's disease. Dr. Rosenberg is a recipient of a K08 training grant from the National Institute on Aging and American Federation for Aging Research “PET imaging of microglial activation in Alzheimer’s disease” and a 2008 Paul Beeson Scholar. Learn more about Dr. Rosenberg
Johns Hopking Alzheimers Studies - Volunteer for research